{"id":"NCT01889251","sponsor":"Alcon Research","briefTitle":"A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion","officialTitle":"A Phase III Study of A01016 125Î¼g Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2013-06-28","resultsPosted":"2015-10-29","lastUpdate":"2015-11-30"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Symptomatic Vitreomacular Adhesion"],"interventions":[{"type":"DRUG","name":"Ocriplasmin","otherNames":["A01016"]},{"type":"DRUG","name":"Sham injection","otherNames":[]}],"arms":[{"label":"Ocriplasmin","type":"EXPERIMENTAL"},{"label":"Sham injection","type":"SHAM_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.","primaryOutcome":{"measure":"Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA)","timeFrame":"Day 28","effectByArm":[{"arm":"Ocriplasmin","deltaMin":52.2,"sd":null},{"arm":"Sham Injection","deltaMin":1.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":114},"commonTop":["Conjunctival haemorrhage","Vitreous floaters","Anterior chamber cell","Back pain","Eye pain"]}}